Zealand Pharma A/S
CSE:ZEAL

Watchlist Manager
Zealand Pharma A/S Logo
Zealand Pharma A/S
CSE:ZEAL
Watchlist
Price: 430.9 DKK 2.23%
Market Cap: 30.6B DKK

Wall Street
Price Targets

ZEAL Price Targets Summary
Zealand Pharma A/S

Wall Street analysts forecast ZEAL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ZEAL is 980.22 DKK with a low forecast of 757.5 DKK and a high forecast of 1 207.5 DKK.

Lowest
Price Target
757.5 DKK
76% Upside
Average
Price Target
980.22 DKK
127% Upside
Highest
Price Target
1 207.5 DKK
180% Upside
Zealand Pharma A/S Competitors:
Price Targets
SPRO
Spero Therapeutics Inc
603% Upside
1952
Everest Medicines Ltd
14% Upside
AVTE
Aerovate Therapeutics Inc
13% Downside
OXB
Oxford BioMedica PLC
85% Upside
302440
SK Bioscience Co Ltd
20% Upside
ORY
Oryzon Genomics SA
184% Upside
2162
KeyMed Biosciences Inc
34% Upside
688363
Bloomage Biotechnology Corp Ltd
5% Upside

Revenue
Forecast

Revenue Estimate
Zealand Pharma A/S

For the last 8 years the compound annual growth rate for Zealand Pharma A/S's revenue is -15%. The projected CAGR for the next 3 years is 205%.

-15%
Past Growth
205%
Estimated Growth
Estimates Accuracy
-23%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Zealand Pharma A/S

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-7%
Average Miss

Net Income
Forecast

Net Income Estimate
Zealand Pharma A/S

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-33%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ZEAL's stock price target?
Price Target
980.22 DKK

According to Wall Street analysts, the average 1-year price target for ZEAL is 980.22 DKK with a low forecast of 757.5 DKK and a high forecast of 1 207.5 DKK.

What is Zealand Pharma A/S's Revenue forecast?
Projected CAGR
205%

For the last 8 years the compound annual growth rate for Zealand Pharma A/S's revenue is -15%. The projected CAGR for the next 3 years is 205%.

Back to Top